Celgene gets Blue Cross Blue Shield's US antitrust claims over Pomalyst dismissed
( March 31, 2025, 12:00 GMT | Official Statement) -- MLex Summary: A US judge has granted motions filed by Celgene, Anthony Insogna, and Jerome Zeldis to dismiss antitrust claims filed by Blue Cross Blue Shield accusing them of illegally monopolizing the market for pomalidomide, a treatment for multiple myeloma sold under the name Pomalyst.See attached document....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.